Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Littlejohn

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Clinical Rheumatology|July 5, 2023
Burden of disease and real-world treatment patterns of patients with systemic lupus erythematosus in the Australian OPAL datasetSabina Ciciriello, Geoffrey Littlejohn, Catherine O'Sullivan, et al.
Occupational Medicine (Oxford, England)|August 2, 2003
Towards epidemiological criteria for soft-tissue disorders of the armPhilip S Helliwell, Robert M Bennett, Geoffrey Littlejohn, et al.
Clinical Rheumatology|August 9, 2021
Real-world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in AustraliaPaul Bird, Geoffrey Littlejohn, Belinda Butcher, et al.
Pain Reports|August 17, 2022
Chronic primary musculoskeletal pain: a new concept of nonstructural regional painMary-Ann Fitzcharles, Steven P Cohen, Daniel J Clauw, et al.
Lancet (London, England)|June 1, 2021
Nociplastic pain: towards an understanding of prevalent pain conditionsMary-Ann Fitzcharles, Steven P Cohen, Daniel J Clauw, et al.
The Clinical Journal of Pain|May 21, 2009
A 1-year safety and efficacy study of duloxetine in patients with fibromyalgiaAmy S Chappell, Geoffrey Littlejohn, Daniel K Kajdasz, et al.
Nature Reviews. Disease Primers|May 19, 2016
FibromyalgiaWinfried Häuser, Jacob Ablin, Mary-Ann Fitzcharles, et al.
Clinical Rheumatology|April 18, 2024
Optimising patient outcomes: temporal trends in remission rates of rheumatoid arthritis patients in the Australian OPAL dataset between 2009 and 2022Geoffrey Littlejohn, Nithila Anbumurali, Catherine O'Sullivan, et al.
Clinical Rheumatology|March 12, 2020
Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in AustraliaPaul Bird, Geoffrey Littlejohn, Belinda Butcher, et al.
Internal Medicine Journal|July 4, 2018
Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REALDave Nicholls, Rina Barrett, Peter Button, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Clinical Rheumatology|July 5, 2023
Burden of disease and real-world treatment patterns of patients with systemic lupus erythematosus in the Australian OPAL datasetSabina Ciciriello, Geoffrey Littlejohn, Catherine O'Sullivan, et al.
Occupational Medicine (Oxford, England)|August 2, 2003
Towards epidemiological criteria for soft-tissue disorders of the armPhilip S Helliwell, Robert M Bennett, Geoffrey Littlejohn, et al.
Clinical Rheumatology|August 9, 2021
Real-world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in AustraliaPaul Bird, Geoffrey Littlejohn, Belinda Butcher, et al.
Pain Reports|August 17, 2022
Chronic primary musculoskeletal pain: a new concept of nonstructural regional painMary-Ann Fitzcharles, Steven P Cohen, Daniel J Clauw, et al.
Lancet (London, England)|June 1, 2021
Nociplastic pain: towards an understanding of prevalent pain conditionsMary-Ann Fitzcharles, Steven P Cohen, Daniel J Clauw, et al.
The Clinical Journal of Pain|May 21, 2009
A 1-year safety and efficacy study of duloxetine in patients with fibromyalgiaAmy S Chappell, Geoffrey Littlejohn, Daniel K Kajdasz, et al.
Nature Reviews. Disease Primers|May 19, 2016
FibromyalgiaWinfried Häuser, Jacob Ablin, Mary-Ann Fitzcharles, et al.
Clinical Rheumatology|April 18, 2024
Optimising patient outcomes: temporal trends in remission rates of rheumatoid arthritis patients in the Australian OPAL dataset between 2009 and 2022Geoffrey Littlejohn, Nithila Anbumurali, Catherine O'Sullivan, et al.
Clinical Rheumatology|March 12, 2020
Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in AustraliaPaul Bird, Geoffrey Littlejohn, Belinda Butcher, et al.
Internal Medicine Journal|July 4, 2018
Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REALDave Nicholls, Rina Barrett, Peter Button, et al.
Pageof 5